Results 171 to 180 of about 10,331,359 (299)

Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024. [PDF]

Infect Dis Ther
Perez KK, Date K, Aliabadi N, Judy J, Landi S, Chilson E, Gessner BD, Begier E.   +7 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

Arthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. [PDF]

Infect Dis Ther
Yarnoff B, Beuvelet M, Soudani S, Neary MP, Hodges EN, Chit A, Tribaldos M, Gabriel V, Musci R, Geurtsen J, Krilov LR.   +10 more
europepmc   +1 more source

Role of Eaton Agent in Disease of Lower Respiratory Tract [PDF]

BMJ, 1960
M K, COOK, R M, CHANOCK, H H, FOX, R J, HUEBNER, E L, BUESCHER, R T, JOHNSON   +5 more
openaire   +2 more sources

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis. [PDF]

Open Forum Infect Dis
Ku JH, Qian L, Sy LS, Ackerson BK, Rayens E, Luo Y, Qiu S, Xu L, Lee GS, Modha PP, Hoke CF, Joe C, Amundsen BI, Pirçon JY, Harrington L, Lecrenier N, Singer D, La EM, Allmon AG, Luyts D, Tseng HF.   +20 more
europepmc   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Acute coronary syndrome after an infective exacerbation of COPD: a prospective cohort study of acute lower respiratory tract disease in hospitalised adults. [PDF]

ERJ Open Res
Morgan C, Challen R, Begier E, Southern J, Nava G, Qian G, McGuinness S, King J, Maskell N, Lahuerta M, Oliver J, Gessner BD, Finn A, Danon L, Hyams C, Dodd JW.   +15 more
europepmc   +1 more source